Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities

about

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities

Item

http://www.wikidata.org/entity/Q41835826

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Role of Systemic Antibiotics i ...... bitors-induced Skin Toxicities

@en

type

Item

label

Role of Systemic Antibiotics i ...... bitors-induced Skin Toxicities

@en

prefLabel

Role of Systemic Antibiotics i ...... bitors-induced Skin Toxicities

@en

P1476

Role of Systemic Antibiotics i ...... bitors-induced Skin Toxicities

@en

P2093

Philomena Charlotte Dsouza

http://www.w3.org/2001/XMLSchema#string

Shiyam Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

P304

323-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/APJON.APJON_28_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28966961

http://www.w3.org/2001/XMLSchema#string

P921

antibiotic

P932

5559943

http://www.w3.org/2001/XMLSchema#string